Cannabis Science (CBIS)
While most of the stocks that have gone hog-wild during the recent wave of marijuana mania, Cannabis Science (CBIS) — like GW Pharmaceuticals — is intensely focused on turning cannabinoids into prescription medications. Specifically, Cannabis Science is taking aim at HIV/AIDS and cancer, with two separate studies, both of which are in pre-clinical stages right now.
Ergo, CBIS stock could be grouped with biotech stocks just as easily at could be lumped in with marijuana stocks.
Whatever the categorization, though, the 270% gain Cannabis Science shares have doled out this year makes it one of the market’s very best.